anonymous
Guest
anonymous
Guest
so many changes in category and markets. What's next?
so many changes in category and markets. What's next?
Great hire! A toothpaste broad with no RX experience. Sounds like just what the company needed. Seriously, this is what they come up with? But at least she's a Brit. GSK will trumpet diversity as the stock retreats into the 30's. Break it up Enema and maybe I'll change my mind about this disaster.
Purrrrrfect for cover ups.How dare you call her a toothpaste broad........ she is a cosmetics broad.
Emma comes in with instant credibility. GSK sensodyne sales were £78M globally last year, up 4% yoy.
Emma comes in with instant credibility. GSK sensodyne sales were £78M globally last year, up 4% yoy.
And that blip noise was the drop falling into the bucket.
So, about the same amount as Dimwitty's payout. I think he should get a 4 rating for this year.
Only GSK can disappoint the street with a new CEO announcement given how much they were looking forward to the end of the Twitty era. And yet, GSK even managed to screw this one up as well.
Hello $40/share.
Emma will be great. Let's stop kidding ourselves about the Pharma business, it's not that difficult. It's about Leadership, Innovation and Business Management. Emma has a proven track record.